The Safety of Olanzapine in Young Children: A Systematic Review and Meta-Analysis

Drug Safety

Volumn 37, Issue 10, 2014, Pages 791-804

  Flank, Jacqueline ^a   Sung, Lillian ^b   Dvorak, Christopher C ^c   Spettigue, Wendy ^d   Dupuis, L Lee ^b  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BENZATROPINE; CHOLESTEROL; GLUCOSE; OLANZAPINE; PROLACTIN; TRIACYLGLYCEROL; BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT;

ADVERSE OUTCOME; AGITATION; CASE REPORT; CASE STUDY; CATATONIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHILD SAFETY; CHOLESTEROL BLOOD LEVEL; COMMON COLD; CONSTIPATION; DROWSINESS; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG INTOXICATION; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ECG ABNORMALITY; EXTRAPYRAMIDAL SYMPTOM; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; HAND TREMOR; HEART ARRHYTHMIA; HEART VENTRICLE HYPERTROPHY; HUMAN; INCREASED APPETITE; LETHARGY; LIVER FUNCTION TEST; META ANALYSIS; METABOLIC SYNDROME X; NEUROLEPTIC MALIGNANT SYNDROME; OFF LABEL DRUG USE; OPEN STUDY; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; PROSPECTIVE STUDY; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RETROSPECTIVE STUDY; REVIEW; SEDATION; SIDE EFFECT; SINGLE BLIND PROCEDURE; SINUS TACHYCARDIA; SOMNOLENCE; SUPRAVENTRICULAR PREMATURE BEAT; SYSTEMATIC REVIEW; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; APPETITE; CHILD; CONSCIOUS SEDATION; DRUG EFFECTS; INFANT; NAUSEA; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA; VOMITING;

ANTIPSYCHOTIC AGENTS; APPETITE; BENZODIAZEPINES; CHILD; CHILD, PRESCHOOL; CONSCIOUS SEDATION; HUMANS; INFANT; NAUSEA; VOMITING; WEIGHT GAIN;

EID: 84925783502     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.1007/s40264-014-0219-y     Document Type: Review

References (67)

1. Cheng-Shannon J, McGough JJ, Pataki C, McCracken JT. Second-generation antipsychotic medications in children and adolescents. J Child Adolesc Psychopharmacol. 2004;14(3):372–94.
2. Olfson M, Crystal S, Huang C, Gerhard T. Trends in antipsychotic drug use by very young, privately insured children. J Am Acad Child Adolesc Psychiatry. 2010;49(1):13–23 00004583-201001000-00005 [pii].
3. Pfeifer JC, Kowatch RA, DelBello MP. Pharmacotherapy of bipolar disorder in children and adolescents: recent progress. CNS Drugs. 2010;24(7):575–93. doi:10.2165/11533110-000000000-00000.
4. Masi G. Pharmacotherapy of pervasive developmental disorders in children and adolescents. CNS Drugs. 2004;18(14):1031–52.
5. Eli Lilly and Company. Zyprexa prescribing information. Indianapolis: Eli Lilly and Co.; 2010.
6. Almandil NB, Liu Y, Murray ML, Besag FMC, Aitchison KJ, Wong ICK. Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis. Paediatr Drugs. 2013;15(2):139–50. doi:10.1007/s40272-013-0016-6.
7. Cohen D, Bonnot O, Bodeau N, Consoli A, Laurent C. Adverse effects of second-generation antipsychotics in children and adolescents: a Bayesian meta-analysis. J Clin Psychopharmacol. 2012;32(3):309–16. doi:10.1097/JCP.0b013e3182549259.
8. Norris ML, Spettigue W, Buchholz A, Henderson KA, Gomez R, Maras D, et al. Olanzapine use for the adjunctive treatment of adolescents with anorexia nervosa. J Child Adolesc Psychopharmacol. 2011;21(3):213–20. doi:10.1089/cap.2010.0131.
9. Navari R, Gray S, Kerr A. Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting (CINV): a randomized phase III trial. [abstract]. J Clin Oncol. 2010;28:641s.
10. Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2013;21(6):1655–63. doi:10.1007/s00520-012-1710-6.
11. Navari RM, Einhorn LH, Loehrer PJ Sr, Passik SD, Vinson J, McClean J, et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer. 2007;15(11):1285–91.
12. Passik SD, Kirsh KL, Theobald DE, Dickerson P, Trowbridge R, Gray D, et al. A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Sympt Manag. 2003;25(5):485–8.
13. Hocking CM, Kichenadasse G. Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. Support Care Cancer. 2014;22(4):1143–51. doi:10.1007/s00520-014-2138-y.
14. Dupuis LL, Boodhan S, Holdsworth M, Robinson PD, Hain R, Portwine C, et al. Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients. Pediatr Blood Cancer. 2013;60:1073–82.
15. Dupuis LL, Milne-Wren C, Cassidy M, Barrera M, Portwine C, Johnston DL, et al. Symptom assessment in children receiving cancer therapy: the parents’ perspective. Support Care Cancer. 2010;18(3):281–99. doi:10.1007/s00520-009-0651-1.
16. Hayden JA, van der Windt DA, Cartwright JL, Côté P, Bombardier C. Assessing bias in studies of prognostic factors. Annal Intern Med. 2013;158(4):280–6.
17. Hollander E, Wasserman S, Swanson EN, Chaplin W, Schapiro ML, Zagursky K, et al. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol. 2006;16(5):541–8.
18. Shaw P, Sporn A, Gogtay N, Overman GP, Greenstein D, Gochman P, et al. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry. 2006;63(7):721–30.
19. Wozniak J, Mick E, Waxmonsky J, Kotarski M, Hantsoo L, Biederman J. Comparison of open-label, 8-week trials of olanzapine monotherapy and topiramate augmentation of olanzapine for the treatment of pediatric bipolar disorder. J Child Adolesc Psychopharmacol. 2009;19(5):539–45. doi:10.1089/cap.2009.0042.
20. McCracken JT, Suddath R, Chang S, Thakur S, Piacentini J. Effectiveness and tolerability of open label olanzapine in children and adolescents with Tourette syndrome. J Child Adolesc Psychopharmacol. 2008;18(5):501–8. doi:10.1089/cap.2007.135.
21. Fido A, Al-Saad S. Olanzapine in the treatment of behavioral problems associated with autism: an open-label trial in Kuwait. Med Princ Pract. 2008;17(5):415–8. doi:10.1159/000141508.
22. Quintana H, Wilson MS 2nd, Purnell W, Layman AK, Mercante D. An open-label study of olanzapine in children and adolescents with schizophrenia. J Psychiatr Pract. 2007;13(2):86–96.
23. Milin R, Simeon JG, Batth S, Thatte S, Dare GJ, Walker S. An open trial of olanzapine in children and adolescents with Asperger disorder. J Clin Psychopharmacol. 2006;26(1):90–2.
24. Mozes T, Ebert T, Michal S-E, Spivak B, Weizman A. An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia. J Child Adolesc Psychopharmacol. 2006;16(4):393–403.
25. Biederman J, Mick E, Hammerness P, Harpold T, Aleardi M, Dougherty M, et al. Open-label, 8-week trial of olanzapine and risperidone for the treatment of bipolar disorder in preschool-age children. Biol Psychiatry. 2005;58(7):589–94.
26. Stephens RJ, Bassel C, Sandor P. Olanzapine in the treatment of aggression and tics in children with Tourette’s syndrome—a pilot study. J Child Adolesc Psychopharmacol. 2004;14(2):255–66.
27. Mozes T, Greenberg Y, Spivak B, Tyano S, Weizman A, Mester R. Olanzapine treatment in chronic drug-resistant childhood-onset schizophrenia: an open-label study. J Child Adolesc Psychopharmacol. 2003;13(3):311–7.
28. Ross RG, Novins D, Farley GK, Adler LE. A 1-year open-label trial of olanzapine in school-age children with schizophrenia. J Child Adolesc Psychopharmacol. 2003;13(3):301–9.
29. Kemner C, Willemsen-Swinkels SHN, de Jonge M, Tuynman-Qua H, van Engeland H. Open-label study of olanzapine in children with pervasive developmental disorder. J Clin Psychopharmacol. 2002;22(5):455–60.
30. Frazier JA, Biederman J, Tohen M, Feldman PD, Jacobs TG, Toma V, et al. A prospective open-label treatment trial of olanzapine monotherapy in children and adolescents with bipolar disorder. J Child Adolesc Psychopharmacol. 2001;11(3):239–50.
31. Malone RP, Cater J, Sheikh RM, Choudhury MS, Delaney MA. Olanzapine versus haloperidol in children with autistic disorder: an open pilot study. J Am Acad Child Adolesc Psychiatry. 2001;40(8):887–94.
32. Sholevar EH, Baron DA, Hardie TL. Treatment of childhood-onset schizophrenia with olanzapine. J Child Adolesc Psychopharmacol. 2000;10(2):69–78.
33. Sethi S, Setiya R, Lallar K. Successful treatment of Sydenham chorea with olanzapine. J Pediatric Neurol. 2006;4(3):171–4.
34. Turkel SB, Jacobson J, Munzig E, Tavare CJ. Atypical antipsychotic medications to control symptoms of delirium in children and adolescents. J Child Adolesc Psychopharmacol. 2012;22(2):126–30. doi:10.1089/cap.2011.0084.
35. Turkel SB, Jacobson JR, Tavare CJ. The diagnosis and management of delirium in infancy. J Child Adolesc Psychopharmacol. 2013;23(5):352–6. doi:10.1089/cap.2013.0001.
36. Bengi Semerci Z. Olanzapine in Tourette’s disorder. J Am Acad Child Adolesc Psychiatry. 2000;39(2):140.
37. Bozkurt H, Mukaddes NM. Catatonia in a child with autistic disorder. Turk J Pediatr. 2010;52(4):435–8.
38. Ferreira Maia AP, Boarati MA, Kleinman A, Fu IL. Preschool bipolar disorder: Brazilian children case reports. J Affect Disord. 2007;104(1–3):237–43. doi:10.1016/j.jad.2007.04.003.
39. Emiroglu FNI, Gencer O, Ozbek A. Adjunctive olanzapine treatment in bipolar adolescents responding insufficiently to mood stabilizers. Four case reports. Eur Child Adolesc Psychiatry. 2006;15(8):500–3.
40. Chungh D-S, Kim B-N, Cho S-C. Neuroleptic malignant syndrome due to three atypical antipsychotics in a child. J Psychopharmacol. 2005;19(4):422–5.
41. Beresford C, Hepburn S, Ross RG. Schizophrenia in pre-school children: two case reports with longitudinal follow-up for 6 and 8 years. Clin Child Psychol Psychiatry. 2005;10(3):429–39. doi:10.1177/1359104505053759.
42. Ercan ES, Kutlu A, Varan A, Cikoglu S, Coskunol H, Bayraktar E. Olanzapine treatment of eight adolescent patients with psychosis. Hum Psychopharmacol. 2004;19(1):53–6.
43. Courvoisie HE, Cooke DW, Riddle MA. Olanzapine-induced diabetes in a seven-year-old boy. J Child Adolesc Psychopharmacol. 2004;14(4):612–6.
44. Boachie A, Goldfield GS, Spettigue W. Olanzapine use as an adjunctive treatment for hospitalized children with anorexia nervosa: case reports. Int J Eat Disord. 2003;33(1):98–103.
45. Sheikh RM, Ahmed K. The efficacy of olanzapine, as needed, to treat acute agitation in juveniles. J Child Adolesc Psychopharmacol. 2002;12(1):71–3.
46. Nguyen M, Murphy T. Olanzapine and hypertriglyceridemia. J Am Acad Child Adolesc Psychiatry. 2001;40(2):133.
47. Mehler C, Wewetzer C, Schulze U, Warnke A, Theisen F, Dittmann RW. Olanzapine in children and adolescents with chronic anorexia nervosa. A study of five cases. Eur Child Adolesc Psychiatry. 2001;10(2):151–7.
48. Chang KD, Ketter TA. Mood stabilizer augmentation with olanzapine in acutely manic children. J Child Adolesc Psychopharmacol. 2000;10(1):45–9.
49. Lavid N, Franklin DL, Maguire GA. Management of child and adolescent stuttering with olanzapine: three case reports. Ann Clin Psychiatry. 1999;11(4):233–6.
50. Malek-Ahmadi P, Simonds JF. Olanzapine for autistic disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry. 1998;37(9):902.
51. Krishnamoorthy J, King BH. Open-label olanzapine treatment in five preadolescent children. J Child Adolesc Psychopharmacol. 1998;8(2):107–13.
52. Horrigan JP, Barnhill LJ, Courvoisie HE. Olanzapine in PDD. J Am Acad Child Adolesc Psychiatry. 1997;36(9):1166–7.
53. Taskiran S, Coffey DBJ. Unremitting impulsive aggression in a child with childhood onset schizophrenia and pervasive development disorder-not otherwise specified: the role of stimulants, atypical antipsychotics and mood stabilizers. J Child Adolesc Psychopharmacol. 2013;23(5):363–6. doi:10.1089/cap.2013.2353.
54. Herguner S. Excessive masturbation associated with olanzapine in a pediatric case. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(7):1349–50. doi:10.1016/j.pnpbp.2010.06.017.
55. Tanoshima R, Chandranipapongse W, Colantonio D, Stefan C, Nulman I. Acute olanzapine overdose in a toddler: A case report. Ther Drug Monit. 2013;. doi:10.1097/FTD.0b013e3182953ed8.
56. Hail SL, Obafemi A, Kleinschmidt KC. Successful management of olanzapine-induced anticholinergic agitation and delirium with a continuous intravenous infusion of physostigmine in a pediatric patient. Clin Toxicol (Phila). 2013;51(3):162–6. doi:10.3109/15563650.2013.773006.
57. Lankheet NAG, Padberg RD, de Kluiver EM, Wilhelm AJ, van Woensel JBM, Beijnen JH, et al. Relatively mild symptoms after an olanzapine intoxication in a 2-year-old girl with excessively high serum levels. J Child Adolesc Psychopharmacol. 2011;21(1):93–5. doi:10.1089/cap.2010.0110.
58. Kochhar S, Nwokike JN, Jankowitz B, Sholevar EH, Abed T, Baron DA. Olanzapine overdose: a pediatric case report. J Child Adolesc Psychopharmacol. 2002;12(4):351–3.
59. Catalano G, Cooper DS, Catalano MC, Butera AS. Olanzapine overdose in an 18-month-old child. J Child Adolesc Psychopharmacol. 1999;9(4):267–71.
60. Bonin MM, Burkhart KK. Olanzapine overdose in a 1-year-old male. Pediatr Emerg Care. 1999;15(4):266–7.
61. Bond GR, Thompson JD. Olanzapine pediatric overdose. Ann Emerg Med. 1999;34(2):292–3.
62. Yip L, Dart RC, Graham K. Olanzapine toxicity in a toddler. Pediatrics. 1998;102(6):1494.
63. Chambers RA, Caracansi A, Weiss G. Olanzapine overdose cause of acute extrapyramidal symptoms. Am J Psychiatry. 1998;155(11):1630–1.
64. Robertson MD, McMullin MM. Olanzapine concentrations in clinical serum and postmortem blood specimens—when does therapeutic become toxic? J Forensic Sci. 2000;45(2):418–21.
65. Ross R, Novins D, Farley G, Adler L. A 1-year open-label trial of olanzapine in school-age children with schizophrenia. J Child Adolesc Psychopharmacol. 2003;13:301–9.
66. Martinez-Ortega JM, Funes-Godoy S, Diaz-Atienza F, Gutierrez-Rojas L, Perez-Costillas L, Gurpegui M. Weight gain and increase of body mass index among children and adolescents treated with antipsychotics: a critical review. Eur Child Adolesc Psychiatry. 2013;22(8):457–79. doi:10.1007/s00787-013-0399-5.
67. Meli M, Rauber-Lüthy C, Hoffmann-Walbeck P, Reinecke HJ, Prasa D, Stedtler U et al. Atypical antipsychotic poisoning in young children: a multicentre analysis of poisons centres data. Eur J Pediatrics. 2013:1–8. doi:10.1007/s00431-013-2241-y.